Final results of a phase I trial of oral vorinostat (Suberoylanilide hydroxamic acid, SAHA) in patients with advanced multiple myeloma

被引：5
|
作者：
Richardson, Paul G. [1 ]
Mitsiades, Constantine S. [1 ]
Colson, Kathleen [1 ]
Reilly, Eileen [2 ]
McBride, Laura [2 ]
Chiao, Judy
Sun, Linda
Ricker, Justin L. [3 ]
Rizvi, Syed [3 ]
Oerth, Carol [3 ]
Atkins, Barbara [3 ]
Fearen, Ivy
Anderson, Kenneth C. [1 ]
Siegel, David S. [2 ]
机构：
[1] Harvard Med Sch, Dana Farber Canc Inst, Boston, MA USA
[2] Hackensack Univ, Med Ctr, Ctr Canc, Hackensack, NJ USA
[3] Merck Res Labs, Upper Gwynedd, PA USA
来源：
BLOOD | 2007年 / 110卷 / 11期
关键词：
D O I：
10.1182/blood.V110.11.1179.1179
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1179
引用
收藏
页码：357A / 357A
页数：1
相关论文
共 50 条
  • [11] Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma, (CTCL)
    Duvic, Madeleine
    Talpur, Rakshandra
    Ni, Xiao
    Zhang, Chunlei
    Hazarika, Parul
    Kelly, Cecilia
    Chiao, Judy H.
    Reilly, John F.
    Ricker, Justin L.
    Richon, Victoria M.
    Frankel, Stanley R.
    BLOOD, 2007, 109 (01) : 31 - 39
  • [12] A phase I clinical trial of an oral formulation of the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA)
    Kelly, W
    O'Connor, O
    Richon, VM
    Tong, W
    Rao, TD
    Chiao, J
    O'Brien, JP
    Rifkid, RA
    Marks, PA
    Scher, HI
    EUROPEAN JOURNAL OF CANCER, 2002, 38 : S88 - S88
  • [13] Vorinostat (suberoylanilide hydroxamic acid, SAHA) is clinically active in advanced cutaneous T-cell lymphoma (CTCL): Results of a phase IIb trial.
    Olsen, E.
    Kim, Y. H.
    Kuzel, T.
    Pacheco, T. R.
    Foss, F.
    Parker, S.
    Wang, J. G.
    Frankel, S. R.
    Lis, J.
    Duvic, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 422S - 422S
  • [14] Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes
    Garcia-Manero, Guillermo
    Yang, Hui
    Bueso-Ramos, Carlos
    Ferrajoli, Alessandra
    Cortes, Jorge
    Wierda, William G.
    Faderl, Stefan
    Koller, Charles
    Morris, Gail
    Rosner, Gary
    Loboda, Andrey
    Fantin, Valeria R.
    Randolph, Sophia S.
    Hardwick, James S.
    Reilly, John F.
    Chen, Cong
    Ricker, Justin L.
    Secrist, J. Paul
    Richon, Victoria M.
    Frankel, Stanley R.
    Kantarjian, Hagop M.
    BLOOD, 2008, 111 (03) : 1060 - 1066
  • [15] Phase II trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in relapsed diffuse large B-cell lymphoma (DLBCL)
    Crump, M.
    Coiffier, B.
    Jacobsen, E. D.
    Sun, L.
    Ricker, J. L.
    Xie, H.
    Frankel, S. R.
    Randolph, S. S.
    Cheson, B. D.
    EJC SUPPLEMENTS, 2007, 5 (04): : 346 - 346
  • [16] Phase I study of vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients (pts) with non-Hodgkin lymphoma (NHL) in Japan
    Tobinai, K.
    Watanabe, T.
    Kobayashi, Y.
    Yamasaki, S.
    Morita-Hoshi, Y.
    Yokoyama, H.
    Morishima, Y.
    Kato, H.
    Frankel, S. R.
    Otsuki, T.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [17] PHASE I TRIAL OF ORAL VORINOSTAT IN COMBINATION WITH BORTEZOMIB IN ADVANCED MULTIPLE MYELOMA
    Weber, D. M.
    Jagannah, S.
    Mazumder, A.
    Sobecks, R.
    Schiller, G. J.
    Gavino, M.
    Meehan, K.
    McFadden, C.
    Chen, C.
    Ricker, J. L.
    Rizvi, S.
    Oerth, C.
    Brownell, P.
    Sanz-Rodriguez, C.
    Hussein, M. A.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 257 - 257
  • [18] Final results of a phase I study of the histone deacetylase inhibitor vorinostat (suberoyanilide hydroxamic acid, SAHA), in patients with leukemia and myelodysplastic syndrome
    Garcia-Manero, G
    Yang, H
    Sanchez-Gonzalez, B
    Verstovsek, S
    Ferrajoli, A
    Keating, M
    Andreeff, M
    O'Brien, S
    Cortes, J
    Wierda, W
    Faderl, S
    Koller, C
    Davis, J
    Morris, G
    Issa, JP
    Frankel, SR
    Richon, V
    Fine, B
    Kantarjian, H
    BLOOD, 2005, 106 (11) : 785A - 785A
  • [19] Phase I study of vorinostat (suberoylanilide hydroxamic acid [SAHA]) in combination with temozolomide in patients with malignant gliomas (NABTC 04-03)
    Wen, Patrick
    Puduvalli, Vinay
    Kuhn, John
    Reid, Joel
    Cloughesy, Timothy
    Yung, Wka
    Drappatz, Jan
    Lamborn, Kathleen
    Gilbert, Mark
    Butowski, Nicholas
    Levin, Victor
    Chang, Susan
    Kesari, Santosh
    Robbins, Hi
    McGovern, Renee
    Richon, Victoria
    Frankel, Stanley
    Ames, Matthew
    Zweibel, James
    Prados, Michael
    NEURO-ONCOLOGY, 2007, 9 (04) : 518 - 518
  • [20] A phase I study of vorinostat (suberoylanilide hydroxamic acid, SAHA) in combination with 5-fluorouracil, leucovorin, and oxaliplatin (FOLFOX) in patients with advanced colorectal cancer (CRC).
    Fakih, M. G.
    Pendyala, L.
    Toth, K.
    Creaven, P.
    Soehnlein, N.
    Litwin, A.
    Trump, D.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 168S - 168S
12345